六国化工(600470) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was CNY 1,167,447,145.87, a decrease of 22.77% compared to CNY 1,511,436,473.03 in the same period last year[5] - Net profit attributable to shareholders was CNY 4,646,118.87, down 65.38% from CNY 14,692,971.46 year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY -8,203,587.03, a decline of 184.65% compared to CNY 9,691,316.45 in the previous year[5] - Basic and diluted earnings per share were both CNY 0.01, representing a decrease of 66.67% from CNY 0.03 in the same period last year[6] - The weighted average return on equity decreased to 0.26%, down 0.49 percentage points from 0.81%[6] - Total operating revenue for Q1 2024 was ¥1,167,447,145.87, a decrease of 22.7% compared to ¥1,511,597,944.80 in Q1 2023[18] - Net profit for Q1 2024 was ¥12,963,705.10, a decline of 40.6% from ¥21,876,349.18 in Q1 2023[19] - Earnings per share for Q1 2024 were ¥0.01, compared to ¥0.03 in Q1 2023[19] Cash Flow and Liquidity - Cash flow from operating activities was CNY -374,600,655.73, compared to CNY -323,440,291.61 in the previous year[6] - In Q1 2024, the company's cash inflow from operating activities was CNY 950,636,941.12, a decrease of 26.67% compared to CNY 1,296,882,805.32 in Q1 2023[22] - The net cash outflow from operating activities was CNY -374,600,655.73, compared to CNY -325,019,673.27 in the same period last year, indicating a worsening cash flow situation[22] - The total cash and cash equivalents at the end of Q1 2024 were CNY 456,517,120.19, down from CNY 623,217,768.75 at the end of Q1 2023[23] - The company reported a significant decrease in cash received from sales of goods and services, totaling CNY 887,119,045.60, compared to CNY 1,258,204,279.34 in the previous year, reflecting a decline of 29.5%[22] - The cash paid for purchasing goods and services was CNY 1,169,640,331.72, a decrease of 20.36% from CNY 1,468,570,299.65 in Q1 2023[22] - The company raised CNY 865,500,000.00 from borrowings in Q1 2024, an increase from CNY 831,047,408.80 in Q1 2023, contributing to a net cash inflow from financing activities of CNY 160,374,360.66[23] Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,946,134,017.94, an increase of 0.55% from CNY 5,913,786,825.05 at the end of the previous year[6] - Total liabilities for Q1 2024 were ¥3,985,379,036.75, an increase from ¥3,964,664,954.53 in Q1 2023[16] - The company’s long-term borrowings rose to ¥576,052,534.51 in Q1 2024, compared to ¥438,620,687.05 in Q1 2023[16] - The company’s total equity increased to ¥1,960,754,981.19 in Q1 2024 from ¥1,949,121,870.52 in Q1 2023[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 56,167[11] - The company reported a total of 132,971,744 shares outstanding, with the largest shareholder, Tongling Chemical Industry Group Co., Ltd., holding 100% of these shares[12] - The top ten shareholders include notable individuals such as Dai Wen and Wu Aimin, with holdings of 20,879,879 shares and 4,799,800 shares respectively[12] - The company has not disclosed any significant changes in shareholder relationships or actions regarding share lending for the reporting period[12] Operational Insights - The company experienced a significant decline in product sales and prices, which primarily impacted net profit and earnings per share[9] - The company reported a total of CNY 12,849,705.90 in non-recurring gains and losses for the period[9] - Accounts receivable increased to ¥207,969,884.90 from ¥194,682,631.97, showing a growth of about 6.4%[14] - Inventory rose significantly to ¥1,470,636,208.28 compared to ¥1,217,014,482.35, indicating an increase of approximately 20.8%[14] - The company has not reported any new product developments or technological advancements during this quarter[13] - There are no significant operational changes or strategic initiatives mentioned for the upcoming quarters[13] - The company has not provided any forward-looking guidance or performance outlook for the next reporting period[13] Research and Development - Research and development expenses for Q1 2024 were ¥44,039,976.84, down from ¥50,441,664.10 in Q1 2023[18] Financial Statement Status - The financial statements for the quarter ending March 31, 2024, have not been audited, indicating a preliminary assessment of financial health[13]